IV immunoglobulin confounds JC virus antibody serostatus determination

Neurology: Neuroimmunology and NeuroInflammation

Volumn 1, Issue 3, 2014, Pages

  Kister, Ilya ^a,b   Kuesters, Geoffrey ^c   Chamot, Eric ^d   Omari, Mirza ^a   Dontas, Kim ^e   Yarussi, Mary ^b   Subramanyam, Meena ^c   Herbert, Joseph ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Barnabas Medical Center   (United States)

^c BIOGEN   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e Specialized Clinical Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; JOHN CUNNINGHAM VIRUS ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANTIBODY BLOOD LEVEL; ARTICLE; HUMAN; INFUSION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POPULATION EXPOSURE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THERAPY EFFECT;

EID: 84978181422     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000029     Document Type: Article

References (20)

1. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010;68:295-303.
2. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoen-cephalopathy. N Engl J Med 2012;366:1870-1880.
3. Subramanyam M, Plavina T, Khatri BO, Fox RJ, Goelz SE. The effect of plasma exchange on serum anti-JC virus antibodies. Mult Scler 2013;19:912-919. doi:10. 1177/1352458512467502.
4. Lichtiger B, Rogge K. Spurious serologic test results in patients receiving infusions of intravenous immune gammaglobulin. Arch Pathol Lab Med 1991;115:467-469.
5. Horst HA, Schmitz N, Glinike C, Löffler H, Laufs R. Seroconversion for hepatitis C virus antibody in bone marrow recipients treated with immune globulin. N Engl J Med 1991;325:132-133.
6. Prohaska W, Wolff C, Schlüter K, Köster-Eiserfunke W, Körner MM, Kleesiek K. Immunoglobulin preparations from hepatitis C antibody-positive plasma donors: influence on diagnosis and risk of infection in heart transplant recipients. Clin Investig 1992;70:573-578.
7. Lopez-Jimenez J, Villalon L, Mateos ML, Odriozola J. Hepatitis C virus antibody seroconversion in bone marrow transplant recipients treated with immune globulin: the impact of the problem. Blood 1994;84:665-666.
8. Bélanger SS, Fish D, Kim J, Cohen S. False-positive human T-lymphotropic virus serology after intravenous immunoglobulin transfusion. CMAJ 2012;184:1709-1712. doi:10.1503/cmaj.120019.
9. Hunter M, Kiernan MC, Post J. Human T-lymphotropic virus seroconversion associated with pooled human intravenous immunoglobulin therapy. Intern Med J 2012;42: 729-730. doi:10.1111/j.1445-5994.2012.02803.x.
10. Rossi KQ, Nickel JR, Wissel ME, et al. Passively acquired treponemal antibody from intravenous immunoglobulin therapy in a pregnant patient. Arch Pathol Lab Med 2002;126:1237-1238.
11. Arnold DM, Crowther MA, Meyer RM, et al. Misleading hepatitis B test results due to intravenous immunoglobulin administration: implications for a clinical trial of rituximab in immune thrombocytopenia. Transfusion 2010;50: 2577-2581.
12. JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2. Available at: http://clinicaltrials.gov/ct2/show/NCT01070836. Accessed January 18, 2014.
13. Achiron A, Kishner I, Dolev M, et al. Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis. J Neurol 2004;251: 1133-1137.
14. Haas J, Hommes OR. A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis. Mult Scler 2007;13:900-908.
15. Elovaara I, Apostolski S, van Doorn P, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol 2008;15:893-908.
16. Fitzmaurice GM, Laird NM, Ware JH. Applied Longitudinal Analysis, 2nd ed. Hoboken, NJ: Wiley; 2011.
17. Bozic C, Richman S, Plavina T, et al. Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol 2011;70:742-750.
18. Trampe AK, Hemmelmann C, Stroet A, et al. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology 2012;78:1736-1742.
19. Outteryck O, Ongagna JC, Duhamel A, et al. Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy. J Neurol 2012;259:2293-2298.
20. Rand KH, Houck H, Ganju A, Babington RG, Elfenbein GJ. Pharmacokinetics of cytomegalovirus specific IgG antibody following intravenous immunoglobulin in bone marrow transplant patients. Bone Marrow Transpl 1989;4:679-683.